Module III: In-Office Applications of Regenerative Therapies: Focus on Cardiovascular, Vascular, and Respiratory Conditions

This module will review disease background, statistics, etiology, current standard of care, and controversies surrounding cardiovascular and pulmonary conditions including: myocardial infarction, atherosclerosis, peripheral artery disease, deep vein thrombosis, asthma, COPD, and interstitial lung disease. And despite advances, restoring function to these damaged systems remains a formidable challenge. This module aims to educate on the recent regenerative research that suggests the adult, embryonic, cardiopoietic, and vascular stem cells may be able to replace damaged heart muscle cells and/or establish new blood vessels to supply them. This module's curriculum will analyze the various cell therapies to gain knowledge on the treatment strategies including patient selection, diagnosis, risks, and benefits.

View Objectives
Physician
(MD, DO, MBBS)
Allied Health

The Fellowship in Stem Cell Therapies: Module III

Online
Add to Cart Add to Cart

Thursday September 22, 2016:

7:30 – 8:00 am

Cardiovascular, Vascular, and Respiratory Disease: A Call to Action

Sharon McQuillan, MD

8:00 – 9:00 am

Cardiovascular Disease: What’s It All About Part One

Doreen Saltiel, MD

9:00 – 10:00 am

Cardiovascular Disease: What’s It All About Part Two

Doreen Saltiel, MD

10:00 – 10:15 am

BREAK

10:15 – 11:00 am

Current Treatment Strategies

Doreen Saltiel, MD

11:00 am – 12:00 pm

Nutritional and Lifestyle Strategies in Heart Disease Management

Stephen Sinatra, MD

12:00 – 1:30 pm

LUNCH

1:30 – 2:30 pm

Cardiogenesis and Heart Disease

Gabriel Nistor, MD

2:30 – 3:00 pm

Factors Influencing CVD Stem Cell Treatment and Delivery Modes

Sharon McQuillan, MD

3:00 – 3:15 pm

BREAK

3:15 – 3:45 pm

Treatment of Myocardial Infarction Utilizing Stem Cells

Thomas Povsic, MD

3:45 – 4:30 pm

Treatment of Refractory Angina Utilizing Stem Cells

Thomas Povsic, MD

4:30 – 5:30 pm

Use of Embryonic and Induced Pluripotent Stem Cells in the Treatment of Cardiovascular Disease

Gabriel Nistor, MD

5:30 – 6:30 pm

Treatment of Cardiovascular Disease Using Bone Marrow-Derived Mononuclear Stem Cells

Jesus Esparragoza, MD

Friday September 23, 2016:

7:30 – 8:30 am

Cell Therapy for the Treatment of Heart Failure

Arshed Quyyumi, MD

8:30 – 9:15 am

Role of Skeletal Myoblasts in Cardiac Repair

Sharon McQuillan, MD

9:15 – 10:15 am

Use of Cardiac Stem Cells and Cardiospheres in the Treatment of Heart Failure

Rafael Gonzalez, PhD

10:15 – 10:30 am

BREAK

10:30 – 11:15 am

Live Case Studies in Regenerative Cardiogenesis

Faculty Panel

11:15 am – 12:15 pm

Vascular Disease Update

Sharon McQuillan, MD

12:15 – 1:30 pm

LUNCH

1:30 – 2:30 pm

Current Vascular Treatment Strategies

Sharon McQuillan, MD

2:30 – 3:00 pm

Angiogenesis and Vascular Disease

Roberto Vazquez-Padron, PhD

3:00 – 3:15 pm

BREAK

3:15 – 4:15 pm

Preclinical studies in Cellular Treatment of Vascular Disease

Roberto Vazquez- Padron, PhD

4:15 – 5:15 pm

Cell Therapy for the Treatment of Peripheral Artery Disease

Arshed Quyyumi, MD

5:15 – 6:00 pm

Live Case Study Evaluations in Translational Vasculogenesis

Faculty Panel

Saturday September 24, 2016:

7:30 – 8:30 am

Respiratory Disease Overview

Robert Bowen, MD

8:30 – 9:30 am

Current Respiratory Disease Treatment Strategies

Robert Bowen, MD

9:30 – 9:45 am

BREAK

9:45 – 10:45 am

Integrative Approaches to Respiratory Disease

Robert Bowen, MD

10:45 – 11:45 am

Regeneration of the Respiratory Epithelium

Gabriel Nistor, MD

11:45 am – 1:15 pm

LUNCH

1:15 – 2:00 pm

COPD

Mukesh Saraiya, MD

2:00 – 2:45 pm

Effects of Extracellular Vesicles in Respiratory Disease

Rafael Gonzalez, PhD

2:45 – 3:00 pm

BREAK

3:00 – 4:00 pm

Preclinical Studies in the Cellular Treatment of Lung Disease

Rafael Gonzalez, PhD

4:00 – 5:00 pm

Mesenchymal Stem Cells in the Treatment of Lung Disease

Sharon McQuillan, MD

5:00 – 6:00 pm

Live Case Studies in Translational Respiratory Disease Treatment

Faculty Panel

View Continuing Education Information

When is this module offered?

Sharon McQuillan, MD

Sharon McQuillan, MD

Sharon McQuillan, MD is a board-certified physician specializing in integrative, regenerative, and aesthetic medicine. She graduated from The Ohio State University School of Medicine and is a member of Alpha Omega Alpha Medical Honors Society. As a board-certified family practitioner, she focused on preventive medicine, diet and exercise, bio-identical hormone replacement, and the mind-body connection long before integrative medicine was mainstream. As a practicing physician, she quickly realized that a healthy self-image is a critical component of optimal health and was one of the first physicians to offer the full spectrum of health, wellness, and cosmetic procedures in her practice. After over twenty years of success in Central Ohio, Dr. McQuillan relocated her practice to Florida, where she further intensified her commitment to individualized medicine by incorporating the healing power of a patient's own stem cells to treat various degenerative conditions. In conjunction with an international team of experts, she has authored over twenty clinical studies utilizing autologous stem cells to treat many common ailments. Dr. McQuillan's passion for teaching, standardization, and superior patient outcomes led her to the formation of Ageless Health, a hands-on training company for medical professionals. Dr. McQuillan has educated thousands of her colleagues in the art and science of integrative, regenerative, and aesthetic medicine. Some of Dr. McQuillan's prestigious titles include Medical Director of both the Aesthetic and Stem Cell and Regenerative Medicine Fellowships for the American Academy of Anti-Aging Medicine. Dr. McQuillan speaks internationally on the subjects of integrative, regenerative, and aesthetic medicine for many organizations and has been featured in numerous national and trade publications. She has appeared on Telemundo and Good Morning America and has made numerous local television appearances. Her commitment to wellness beauty, and successful aging has expanded to other organizations as well. She currently serves as Medical Director for Great HealthWorks, a consumer-directed health and wellness product manufacturer and distributor. As Co-Executive Editor of New You Magazine and Chairman of the New You Medical Advisory Board, she educates the public responsibly in the best practices for successful aging.

Doreen Saltiel, MD, FACC, FMNM, ABAARM

Doreen Saltiel, MD, FACC, FMNM, ABAARM

Doreen Saltiel, MD, FACC, FMNM, ABAARM, after completing a cardiology fellowship and board certification, practiced interventional cardiology for more than 20 years. Additionally, she is board certified in Phlebology and a registered physician in vascular interpretation (RPVI). Dr. Saltiel completed advanced fellowship training in Metabolic and Nutritional Medicine from MMI and is a Diplomate of the American Board of Anti-Aging and Regenerative Medicine. She completed MMI’s advanced certification in Cardiovascular Health and is currently enrolled in the University of South Florida’s (USF) Master’s Program in Metabolic and Nutritional Medicine and USF’s Cardiovascular Advanced Certification.

Robert Bowen, MD

Robert Bowen, MD

Dr. Bowen graduated from the University of Illinois School of Medicine and trained in Internal Medicine, Critical Care, and Pulmonary Medicine at the University of Virginia and West Virginia University medical centers. He was trained in laser bronchoscopy in 1982/1983 and after completing a fellowship in cosmetic antiaging and regenerative medicine extended his laser experience to include aesthetic therapies. He is currently an associate professor of medicine at WVU and director of the Center for Wound Care and Hyperbaric Medicine at WVU Berkeley Medical Center. His current research interests include the translation of adipose derived stem cell treatments and light-based therapies into clinical applications.

Jesus Esparragoza, MD

Jesus Esparragoza, MD

Jesus Esparragoza Romano, MD, is a Fellow of the American College of Cardiology. He graduated in 1977 from the Faculty of Medicine of the Autonomous University of Guadalajara, acquiring the title of Surgeon.

He made his “Fellowship” in Adult Cardiology at the Texas Heart Institute in Houston. He is also Interventional Cardiologist.

He was a pioneer in stem cell therapies, following protocols approved by COFEPRIS. He, along with other doctors, performed the first heart transplant in Guadalajara, Jalisco.

Rafael Gonzalez, Ph.D

Rafael Gonzalez, Ph.D

Dr. Gonzalez serves as Vice President of Research & Development at DaVinci Biosciences and is responsible for the development of clinical stem cell applications for several disease/trauma states. Dr. Gonzalez has been Member of Advisory Board at BioStem Technologies, Inc. since October 2014. Dr. Gonzalez has expertise in degenerative disorders involving the spinal cord and has extensive experience in stem cell culture and biology from human embryonic, pre-natal and adult sources. Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a Research Scientist at PrimeGen Biotech where he was responsible for the design and execution of experiments involving adult (bone marrow, menstrual blood, adipose) and pre-natal stem cells (neural, bone marrow, liver, gonadal) for potential clinical application. Dr. Gonzalez was also responsible for developing PrimeGen's pre-clinical stem cell/spinal cord injury model. Dr. Gonzalez developed his thesis at the Reeve-Irvine Research Center, University of California, Irvine, under the advisory of Dr. Hans Keirstead, entitled: "The Role of the Chemokine CXCL10 in Secondary Degeneration Following Spinal Cord Injury". Pre-clinical studies conducted during this time lead by Dr. Gonzalez were aimed at reducing secondary degenerative effects. The studies conducted by Dr. Gonzalez and Dr. Keirstead precipitated the start-up of Ability Biomedical, a company that developed anti-IP10 antibody, an antibody which can be used to treat several degenerative disorders such as multiple sclerosis, rheumatoid arthritis, and SCI. Ability Biomedical was purchased by Medarex in 2007 which was purchased by Bristol-Myers Squibb that sponsors a phase II clinical trial using anti-IP10 antibody (MDX-1100). He also was involved with preclinical studies in the development of the use of human embryonic stem cells into spinal cord injury. Dr. Gonzalez has several scientific publications in the field of stem cells, spinal cord injury and the immune system. Dr. Gonzalez received his BS in Biological Science and his Ph.D. in Anatomy and Neurobiology from the University of California, Irvine, CA.

Gabriel Nistor, PhD

Gabriel Nistor, PhD

Broad, multidisciplinary knowledge and skills in all science areas with main expertise in biology and medicine. Following residency program, MD practice and postdoctoral studies at University California Irvine, Gabriel Nistor serves as vice president for Research at Caladrius Biotechnology, recognizing 15 years of research leadership in regenerative medicine and cancer immunotherapy.

Thomas Povsic, MD, PhD

Thomas Povsic, MD, PhD

Dr. Thomas Povsic is an associate professor of medicine and interventional cardiologist in the Duke Clinical Research Institute (DCRI) at Duke University Medical Center. He received his Ph.D. in bioorganic chemistry from the California Institute of Technology, his MD at Harvard Medical School and has been on faculty since 2004.

Dr. Povsic’s research experience extends from bench research to phase 3 clinical trials.  His key research interests include the development and translation of novel basic therapeutics to clinical use.  He heads the advanced biomarkers group at the DCRI, focusing on translational research aimed to foster better understanding of mechanisms of action, off target affects, and modulators of efficacy. He has a particular interest in understanding the role of progenitor cell mediated repair on the development of vascular disease and establishing regenerative therapies for treatment of cardiovascular conditions.  He has led a laboratory interested in the assessment of endothelial progenitor cells (EPCs) in a variety of clinical conditions, as well as led several clinical trials of regenerative therapies. He was the national principal investigator of the RENEW trial exploring the use of autologous CD34+ cell for the treatment of refractory angina as well as CHART-2, a trial of autologous bone marrow cells augmented for cardiopoiesis for the treatment of congestive heart failure, and is a member of the Transatlantic Alliance for Cell Therapy In Cardiovascular Syndromes (TACTICS group).

Stephen Sinatra, M.D., F.A.C.C., F.A.C.N., C.N.S.

Stephen Sinatra, M.D., F.A.C.C., F.A.C.N., C.N.S.

Dr. Stephen T. Sinatra is a board-certified cardiologist and an Assistant Clinical Professor of Medicine at the University of Connecticut School of Medicine in Farmington, Connecticut. Certified as a bioenergetic psychotherapist, and nutrition and anti-aging specialist, Dr. Sinatra integrates psychological, nutraceutical and electroceutical therapies in the matrix of healing. He is the founder of www.heartmdinstitute.com, an informational website dedicated to promoting public awareness of integrative medicine. Dr. Sinatra is a fellow in the American College of Cardiology and the American College of Nutrition.  Dr. Sinatra’s latest book, co-authored with Tommy Rosa, is Health Revelations from Heaven and Earth.

Roberto Vazquez-Padron, PhD

Roberto Vazquez-Padron, PhD

Dr. Roberto I. Vazquez-Padron received his Ph.D. in Biology from the University of Havana in 1999, after receiving multiple National Awards from the Cuban Academy of Sciences and being selected as one of the Latin-American Talent Young Investigators by the Biochemistry and Molecular Biology Brazilian Society. In year 2000, he decided to continue his education in the United States toward a more clinically related experience and interdisciplinary training. He was highly motivated by the challenge of finding cures and better treatments for cardiovascular diseases, the number one killer in America. He joined the Cardiothoracic Research Laboratory in the Department of Surgery and the Vascular Biology Institute at the University of Miami, Miller School of Medicine. He engaged in basic science projects to study the molecular mechanism of aged-related vascular diseases. He demonstrated the hyper-proliferative response of aging vascular smooth muscle cells to post injury growth factors. Following four years of postdoctoral training, Dr. Alan Livingstone, Chairman of Surgery, promoted him to Research Assistant Professor. In 2005, using the resources from an American Heart Association Scientific Development Award, he put together his own multidisciplinary laboratory equipped with microsurgery and molecular and cell biology facilities. Currently, he is an NIH-award winning scientist, mentor and professor, focused on understanding the cellular and molecular mechanisms underlying vascular obstructive diseases like atherosclerosis, in-stent restenosis, transplant vasculopathy, and arteriovenous fistula failure. A full-time scientist, post-doctoral fellows and graduate students currently form his lab. His laboratory is currently supported by three major NIH grants. He has published +60 peer-reviewed scientific articles and book chapters and presented his work in multiple national and international meetings. He is currently a member of the NHLBI Mentored Clinical and Basic Science Review Committee and the NIH Cardiovascular and Respiratory Sciences (CVRS) Integrated Fellowship Review Group. He was a member of the American Heart Association’s Vascular Wall Angiogenesis, Atherosclerosis, General and Inflammation Peer Review Committee (2010-2015). He serves as reviewer of multiple indexed journals. Apart from his work in academia, he is a founder of the Miami Cardiovascular Innovations Corp.

Arshed Ali Quyyumi, MD, FRCP, FACC

Arshed Ali Quyyumi, MD, FRCP, FACC

Dr. Quyyumi is currently a tenured Professor of Medicine in the Division of Cardiology at Emory University School of Medicine and Co-Director at Emory Clinical Cardiovascular Research Institute.  He is Board certified in Internal Medicine and Cardiology, and is a Fellow of the Royal College of Medicine. 
He graduated from Guy’s Hospital medical school in London, and after accomplishing part of his medicine and cardiology training in London, he completed his fellowship training at Massachusetts general Hospital, Harvard University in Boston and at the National Institutes of Health (NIH), Bethesda, Maryland.  He was a Senior Investigator and director of the cardiac catheterization laboratory at the Cardiology Branch of the National Institutes of Health for several years before arriving at Emory.

His research focus over the last quarter century has been on clinical and translational research in vascular biology, progenitor cells and angiogenesis, biomarkers and cardiovascular genomics.  He has performed seminal studies investigating mechanisms of myocardial ischemia including silent ischemia in the past. His current studies include comprehensive assessment of vascular endothelial function and arterial stiffness and thickness in patients with arteriosclerosis and its risk factors.  Other studies investigate the role of genetic and environmental risks on vascular disease, and particularly in relation to health disparities.  He is also conducting clinical trials with bone marrow derived stem cells and progenitors in cardiovascular disease.  He has published over 300 manuscripts in peer-reviewed journals.

Educationally Partnered With

USF Logo A4M LogoWashington Logo
White Bottom Arrow